| Website | crescendobiologic... |
| Category | BioTech |
| Phone | +44 (0) 1223 497140 |
| Employees |
| TOTAL | $7.3M |
| VENTURE FUNDING TOTAL | $7.3M |
| Series A, 1/10 Sofinnova Ventures Avlar BioVentures Rainbow Seed Fund | $7.3M |
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.
The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
